dual target cCAR-T therapy (Innovation Immunotechnology)

N/A

Report date: 2023/09/05 16:23:12

Base Information

Drug Namedual target cCAR-T therapy (Innovation Immunotechnology)
Drug Alias Namedual target cCAR-T program (Innovation Immunotechnology)靶向CD105和HER2的双靶点复合型嵌合抗原受体T细胞治疗（因诺免疫）
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-HER2Anti-CD105
TargetsEndoglinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Inno Immunization Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Inno Immunization Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A